Midkine (MDK), a heparin-binding growth factor, belongs to the pleiotrophin family and plays critical roles in cellular processes like proliferation, migration, and survival. Initially identified in embryonic tissues, MDK is minimally expressed in healthy adults but is significantly upregulated in various cancers (e.g., neuroblastoma, glioblastoma, prostate cancer) and inflammatory conditions. Its overexpression correlates with tumor progression, angiogenesis, metastasis, and poor prognosis, making it a promising biomarker and therapeutic target.
MDK antibodies are tools designed to detect or inhibit MDK activity. Research-grade antibodies facilitate studying MDK's role in disease mechanisms via techniques like immunohistochemistry and ELISA. Therapeutically, neutralizing MDK antibodies aim to block its interaction with receptors (e.g., LRP1. ALK), suppressing oncogenic signaling. Preclinical studies show such antibodies reduce tumor growth and metastasis in models of breast and lung cancers. Challenges remain in optimizing specificity and delivery, but MDK-targeted therapies, including antibody-drug conjugates, represent a growing area in precision oncology. Overall, MDK antibodies bridge diagnostic, functional, and therapeutic exploration of this multifaceted protein in human diseases.